Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyRalf Reilmann, Hope Heller, Pascale Gauteul et al.|The Lancet Neurology|2018Cited by 108
Brain Regions Showing White Matter Loss in Huntington’s Disease Are Enriched for Synaptic and Metabolic GenesPeter McColgan, D. Crawfurd, C Jauffret et al.|Biological Psychiatry|2017Cited by 104